MXCT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
10.2M
+39.6%
7.3M
-24.7%
9.7M
+32.2%
7.3M
+6.9%
6.8M
Cost of Revenue
1.7M
+0.5%
1.7M
+6.8%
1.6M
-2.5%
1.6M
+0.9%
1.6M
Gross Profit
8.5M
+51.3%
5.6M
-30.8%
8.1M
+42.0%
5.7M
+8.7%
5.2M
Operating Expenses
14.5M
-8.3%
15.8M
+10.9%
14.3M
-15.7%
16.9M
-12.7%
19.4M
R&D
2.9M
-32.4%
4.3M
+10.3%
3.9M
+15.7%
3.3M
-37.3%
5.3M
SG&A
10.8M
+1.4%
10.6M
+13.1%
9.4M
+4.5%
9.0M
-9.8%
10.0M
Operating Income
-6041000
+41.0%
-10232000
-65.4%
-6185000
+44.9%
-11226000
+20.7%
-14149000
EBITDA
-5141000
+44.4%
-9254000
-80.1%
-5138000
-45.1%
-3542000
+64.6%
-10019000
Net Income
-4762000
+46.3%
-8874000
-86.8%
-4750000
+50.5%
-9596000
+22.7%
-12416000
EPS (Basic)
$-0.05
+37.5%
$-0.08
-100.0%
$-0.04
+55.6%
$-0.09
+25.0%
$-0.12
EPS (Diluted)
$-0.05
+37.5%
$-0.08
-100.0%
$-0.04
+55.6%
$-0.09
+25.0%
$-0.12
Shares (Diluted)
103.5M
-3.1%
106.8M
-0.0%
106.9M
+0.1%
106.7M
+0.1%
106.6M
MaxCyte (MXCT) — Financials